Heartwire
Late-Breaking Clinical Trials I
Dimanche 13 novembre 2011, 15 h 45 – 17 h 13
West Hall B4
Modérateurs : Gilles Montalescot et Jeffrey Weitz
Dimanche 13 novembre 2011, 15 h 45 – 17 h 13
West Hall B4
Modérateurs : Gilles Montalescot et Jeffrey Weitz
Télécharger le PDF  |
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: AIDA STEMI trial Dimanche 13 novembre, 15 h 45 – 15 h 55 Holger Thiele (Herzzentrum Leipzig, Allemagne) Discussion et panel : 15 h 55 – 16 h 07 (Commentatrice : Alice Jacobs, Boston University School of Medicine, MA, É.-U.) |
| Abciximab plus unfractionated heparin vs bivalirudin in patients with non–ST–segment-elevation myocardial infarction undergoing percutaneous coronary intervention. The ISAR–REACT 4 randomized trial Dimanche 13 novembre, 16 h 07 – 16 h 17 Adnan Kastrati (Deutsches Herzzentrum, Munich, Allemagne) Discussion et panel : 16 h 17 – 16 h 29 (Commentateur : Deepak Bhatt, Brigham and Women's Hospital, Boston, MA, É.-U.) |
|
| Extended anticoagulant prophylaxis in initially hospitalized medically ill patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial Dimanche 13 novembre, 16 h 29 – 16 h 39 Samuel Goldhaber (Brigham and Women's Hospital, Boston, MA, É.-U.) Discussion et panel : 16 h 39 – 16 h 51 (Commentatrice : Mary Cushman, University of Vermont, Burlington, É.-U.) |
|
| The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA–CER) trial Dimanche 13 novembre, 16 h 51 – 17 h 01 Kenneth Mahaffey (Duke Clinical Research Institute, Durham, NC, É.-U.) Discussion et panel : 17 h 01 – 15 h 13 (Commentateur : Keith Fox, Université d’Édimbourg, Écosse) |
|
| Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome C Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, É.-U.) Dimanche 13 novembre, 17 h 13 – 17 h 23 |
Late-Breaking Clinical Trials II
Lundi 14 novembre, 10 h 45 – 12 h 13
West Hall B4
Modérateurs : Frederick Masoudi et Clyde Yancy
Lundi 14 novembre, 10 h 45 – 12 h 13
West Hall B4
Modérateurs : Frederick Masoudi et Clyde Yancy
|
The impact of full coverage for preventive medications after myocardial infarction on recurrent vascular events: The Post–MI Free Rx Event and Economic Evaluation (Post–MI FREEE) trial Lundi 14 novembre, 10 h 45 – 10 h 55 Niteesh Choudhry (Harvard Medical School, Boston, MA, É.-U.) Discussion et panel : 10 h 55 – 11 h 07 (Commentateur : Eric Peterson, Duke Clinical Research Institute, Durham, NC, É.-U.) |
Pharmacist intervention to prevent hospitalization and death in patients with heart failure: A prospective cluster randomized controlled trial Lundi 14 novembre, 11 h 07 – 11 h 17 Richard Lowrie (National Health Service, Greater Glasgow and Clyde, Glasgow, Écosse) Discussion et panel : 11 h 17 – 11 h 29 (Commentatrice : Mariell Jessup, University of Pennsylvania, Philadelphie, É.-U.) |
| Testing an evidence–based, individualized informed-consent form to improve patients' experiences with PCI Lundi 14 novembre, 11 h 29 – 11 h 39 John Spertus (Mid America Heart Institute, Kansas City, MO, É.-U.) Discussion et panel : 11 h 39 – 11 h 51 (Commentateur : Manesh Patel, Duke Clinical Research Institute, Durham, NC, É.-U.) |
|
| Outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery: A randomized study Lundi 14 novembre, 11 h 51 – 12 h 01 Thomas Aversano (Johns Hopkins Medical Institute, Baltimore, MD, É.-U.) Discussion et panel : 12 h 01 – 12 h 13 (Commentateur : Loren Hiratzka, TriHealth, Cincinnati, OH, É.-U.) |
Late-Breaking Clinical Trials III
Lundi 14 novembre, 15 h 45 – 17 h 13
Chapin Theater
Modérateurs : Alan Camm et Douglas Zipes
Lundi 14 novembre, 15 h 45 – 17 h 13
Chapin Theater
Modérateurs : Alan Camm et Douglas Zipes
|
Double-blind placebo controlled dose ranging study of the efficacy and safety of celivarone 50, 100, or 300 mg od with amiodarone as calibrator for the prevention of ICD interventions or death (ALPHEE) Lundi 14 novembre, 15 h 45 – 15 h 55 Peter Kowey (MLH Heart Center Lankenau Medical Center, Wynnewood, PA, É.-U.) Discussion et panel : 15 h 55 – 16 h 07 (Commentatrice : Cynthia Tracy, Georgetown University Hospital, Washington, DC, É.-U.) |
| Atrial fibrillation catheter ablation vs surgical ablation treatment: A multicenter randomized clinical trial Lundi 14 novembre, 16 h 07 – 16 h 17 Lucas Boersma (Saint Antonius Hospital, Nieuwegein, Pays-Bas) Discussion et panel : 16 h 17 – 16 h 29 (Commentateur : A Marc Gillinov, Cleveland Clinic, OH, É.-U.) |
|
| A randomized multicenter comparison of radiofrequency ablation and antiarrhythmic drug therapy as first-line treatment in 294 patients with paroxysmal atrial fibrillation Lundi 14 novembre, 16 h 29 – 16 h 39 Jens Cosedis Nielsen (Aarhus University Hospital, Skejby, Aarhus N, Danemark) Discussion et panel : 16 h 39 – 16 h 51 (Commentateur : William Stevenson, Brigham and Women's Hospital, Boston, MA, É.-U.) |
|
| The results of the PALLAS study Lundi 14 novembre, 16 h 51 – 17 h 01 Stuart J Connolly (McMaster University, Hamilton, ON, Canada) Discussion et panel : 17 h 01 – 17 h 13 (Commentateur : NA Mark Estes III, Tufts University, Boston, MA, É.-U.) |
Late-Breaking Clinical Trials IV
Mardi 15 novembre, 10 h 45 – 12 h 13
West Hall B4
Modérateurs : John Kastelein et Donald Lloyd–Jones
Mardi 15 novembre, 10 h 45 – 12 h 13
West Hall B4
Modérateurs : John Kastelein et Donald Lloyd–Jones
|
Practice-Based Opportunities for Weight Reduction (POWER}
Mardi 15 novembre, 10 h 45 – 10 h 55 Lawrence Appel (Johns Hopkins, Baltimore, MD, É.-U.) Discussion et panel : 10 h 55 – 11 h 07 (Commentateur : Frank Sacks, Harvard School of Public Health, Boston, MA, É.-U.) |
| Comparison of the progression of coronary atherosclerosis for two high-efficacy statin regimens with different HDL effects: SATURN study results Mardi 15 novembre, 11 h 07 – 11 h 17 Stephen Nicholls (Cleveland Clinic, Cleveland, OH, É.-U.) Discussion et panel : 11 h 17 – 11 h 29 |
|
| Lipid–modulating effects of evacetrapib, a novel CETP inhibitor, administered as monotherapy or in combination with the most commonly used statins Mardi 15 novembre, 11 h 29 – 11 h 39 Stephen Nicholls (Cleveland Clinic, Cleveland, OH, É.-U.) Discussion et panel : 11 h 39 – 11 h 51 (Commentateur : Daniel Rader, University of Pennsylvania, Philadelphie, É.-U.) |
|
| Extended-release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL cholesterol is optimally controlled with statin therapy: Results from the AIM–HIGH trial Mardi 15 novembre, 11 h 51 – 12 h 01 William Boden (University of Buffalo, NY, É.-U.) Discussion et panel : 12 h 01 – 12 h 13 (Commentateur : Philip Barter, University of Sydney, Australie) |
Late-Breaking Clinical Trials V
Mercredi 16 novembre, 10 h 45 – 12 h 13
Room W415 (Valencia Ballroom)
Modérateurs : Valentin Fuster et Patrick O'Gara
Mercredi 16 novembre, 10 h 45 – 12 h 13
Room W415 (Valencia Ballroom)
Modérateurs : Valentin Fuster et Patrick O'Gara
|
Randomized trial of Early Surgery vs Conventional Treatment for Infective Endocarditis (EASE) Mercredi 16 novembre, 10 h 45 – 10 h 55 Duk–Hyun Kang (Asan Medical Center, Séoul, Corée du Sud) Discussion et panel : 10 h 55 – 11 h 07 (Commentateur : Robert Higgins, Ohio State University, Columbus, É.-U.) |
| Claudication treatment comparative effectiveness: Six–month outcomes from the CLEVER study Mercredi 16 novembre, 11 h 07 – 11 h 17 Timothy Murphy (Rhode Island Hospital, Providence, RI, É.-U.) Discussion et panel : 11 h 17 – 11 h 29 (Commentateur : Michael Conte, University of California, San Francisco, É.-U.) |
|
| Colchicine reduces postoperative atrial fibrillation. Results of the COPPS atrial–fibrillation study Mercredi 16 novembre, 11 h 29 – 11 h 39 Massimo Imazio (Hôpital Maria Vittoria, Turin, Italie) Discussion et panel : 11 h 42 – 11 h 51 (Commentatrice : Nancy Nussmeier, SUNY Upstate Medical University, Syracuse, É.-U.) |
|
| ELEVATE–TIMI 56: Escalating clopidogrel by involving a genetic strategy–TIMI 56 Mercredi 16 novembre, 11 h 51 – 12 h 01 Jessica Mega (Brigham and Women's Hospital, Boston, MA, É.-U.) Discussion et panel : 12 h 01 – 12 h 13 (Commentateur : Lawrence Lesko, University of Florida, Gainesville, É.-U.) |
